Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

The main result – reported earlier – was an overall weight reduction of 20.2% with Zepbound at 72 weeks, compared to 13.7% with Wegovy.

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.

Access Ozempic, Wegovy, and Zepbound generics Prescriptions within 24 hours, medicine shipped within 48 hours Unlimited virtual visits with providers at no additional cost ...